LLT1 (CLEC2D)

Class

Anti-LLT1 monoclonal antibody (NK-cell immune checkpoint inhibitor)

Pathway

Blockade of LLT1-mediated NK-cell inhibitory signaling

LLT1 (also called CLEC2D) is a cell-surface protein belonging to the C-type lectin-like receptor family. It is expressed on activated immune cells, antigen-presenting cells, and frequently on tumor cells. Its principal binding partner is CD161 (NKR-P1A), a receptor found on natural killer (NK) cells and subsets of T cells. When LLT1 engages CD161, it delivers an inhibitory signal that restrains the cytotoxic activity and cytokine secretion of these lymphocytes. This inhibitory axis is part of a broader system of checkpoints that keep innate and innate-like immune responses in balance, preventing excessive tissue damage during normal immune surveillance. In cancer, tumor cells can exploit this pathway by upregulating LLT1, effectively dampening NK-cell attack and evading immune clearance. A monoclonal antibody directed against LLT1 is designed to block this ligand-receptor interaction, releasing NK cells (and relevant T-cell subsets) from inhibitory constraint so that their natural cytotoxic and cytokine-producing functions can proceed against malignant or infected cells. This strategy extends the immune checkpoint blockade concept, well established for adaptive immune checkpoints, into the innate immune compartment, and is being explored as a mechanism relevant to solid and hematologic malignancies where NK-cell function is suppressed within the tumor microenvironment.